ROSGQ (Rosetta Genomics) Effective Interest Rate on Debt %: 0.00% (As of Jun. 2017)


What is Rosetta Genomics Effective Interest Rate on Debt %?

Rosetta Genomics ROSGQ Effective Interest Rate on Debt % is 0.00% as of Jun. 2017.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Rosetta Genomics's annualized positive value of Interest Expense for the quarter that ended in Jun. 2017 was $0.00 Mil. Rosetta Genomics's average total debt for the quarter that ended in Jun. 2017 was $3.12 Mil. Therefore, Rosetta Genomics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2017 was 0.00%.

Rosetta Genomics  (OTCPK:ROSGQ) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Rosetta Genomics Effective Interest Rate on Debt % Related Terms

Rosetta Genomics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Rosetta Genomics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics Effective Interest Rate on Debt % Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,063.33 0.00 0.00 0.00 1.13

Rosetta Genomics Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 32.65 57.53 0.00

ROSGQ vs TEAR, IDTA, ABMC: Effective Interest Rate on Debt % Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics Effective Interest Rate on Debt % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Effective Interest Rate on Debt % falls into.


Rosetta Genomics Effective Interest Rate on Debt % Calculation

Rosetta Genomics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2016 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2015 )+Total Debt  (A: Dec. 2016 ))/ count )
=-1  *  -0.043/( (0+3.795)/ 1 )
=-1  *  -0.043/3.795
=1.13 %

where

Total Debt  (A: Dec. 2015 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

Total Debt  (A: Dec. 2016 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.74 + 0.055
=3.795

Rosetta Genomics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2017 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2016 )+Total Debt  (Q: Jun. 2017 ))/ count )
=-1  *  0/( (3.795+2.449)/ 2 )
=-1  *  0/3.122
=0.00 %

where

Total Debt  (Q: Dec. 2016 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.74 + 0.055
=3.795

Total Debt  (Q: Jun. 2017 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.394 + 0.055
=2.449

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Jun. 2017) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 0.00% mean?
Rosetta Genomics (ROSGQ) has a Effective Interest Rate on Debt % of 0.00% as of Jun. 2017. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Effective Interest Rate on Debt % too high?
Rosetta Genomics' current Effective Interest Rate on Debt % is 0.00%.
How does Rosetta Genomics' Effective Interest Rate on Debt % compare to TEAR and IDTA?
Rosetta Genomics' Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Medical Diagnostics & Research company?
A good Effective Interest Rate on Debt % depends on the Medical Diagnostics & Research industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Rosetta Genomics and its competitors. Rosetta Genomics's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Effective Interest Rate on Debt % is 0.00% as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.